54625-34-2

Upstream product

• 2612-02-4 5-methoxysalicylic acid 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 53985-53-8 2-(benzyloxy)-5-methoxybenzoic acid 
• 1285513-33-8 5-(methyloxy)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 284470-02-6 6-[formyl-(2-trimethylsilanyl-ethoxymethoxy)-amino]-2-{[2-(2-hydroxy-5-methoxy-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-hexanoic acid 1-{1-[1-(tert-butyl-diphenyl-silanyloxy)-2-oxo-azepan-3-ylcarbamoyl]-1-methyl-ethyl}-octyl ester 
• 284469-97-2 N-(2-benzyloxy-5-methoxy)benzoyl-L-threonine methyl ester 
• 284469-98-3 methyl 2-[(2-benzyloxy-5-methoxy)phenyl]-5-methyloxazole-4-caboxylate 
• 284469-99-4 methyl 2-[(2-hydroxy-5-methoxy)phenyl]-5-methyloxazole-4-caboxylate 
• 284469-89-2 2-[(2-hydroxy-5-methoxy)phenyl]-5-methyloxazole-4-caboxylic acid 
• 225505-59-9 amamistatin A 

Relevant academic research and scientific papers

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors

Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

Total synthesis of amamistatin A, an antiproliferative linear peptide from an actinomycete

Amamistatin A, a linear lipopeptide and a growth inhibitor of human tumor cell lines from an actinomycete, was efficiently synthesized by a convergent approach. The asymmetric synthesis of β-hydroxy acid fragment was achieved by using chiral oxazaborolidinone mediated aldol reaction. The oxazole ring was constructed from N-acylthreonine via side-chain oxidation and cyclodehydration. The synthesis of the linear peptide was carded out in a stepwise manner from the cyclic hydroxamic acid fragment, and the final deprotection provided amamistatin A. (C) 2000 Elsevier Science Ltd.

Substituted benzoic acid hypolipemic agents

Polysubstituted benzoic acids, and their use in mammals as hypolipemic agents.

(4-Oxo-4H-1-benzopyran-2-yl)-oxamic acid, salts and esters anti-allergic agents

Anti-allergic agents present the following structural formula: SPC1 In which R is --H, lower alkyl or an alkali metal cation. R2 is alkyl of 1 to 6 carbon atoms or hydroxyalkyl of 2 to 6 carbon atoms.